Alterity Therapeutics Limited, a development stage enterprise, has announced the approval of a capital raising initiative through the issuance of options to investors. The announcement, dated December 29, 2023, detailed the approval by shareholders for the issuance of 1,371,428,571 unlisted Short Dated Options and 457,142,857 Long Dated Options, with exercise prices of A$0.007 and A$0.01 respectively. The Short Dated Options will expire on August 31, 2024, while the Long Dated Options, which are proposed to be listed subject to ASX requirements, will expire on August 31, 2026. The options are attached to fully paid ordinary shares under a placement approved at the general meeting on December 29, 2023. The offer is available to invitees determined by the company and closes on January 5, 2024. The announcement also included the resignation of CFO Kathryn Andrews and the appointment of Phillip Hains as the new CFO effective January 31, 2024.

Alterity Therapeutics Limited, a development stage enterprise, has announced the approval of a capital raising initiative through the issuance of options to investors. The announcement, dated December 29, 2023, detailed the approval by shareholders for the issuance of 1,371,428,571 unlisted Short Dated Options and 457,142,857 Long Dated Options, with exercise prices of A$0.007 and A$0.01 respectively. The Short Dated Options will expire on August 31, 2024, while the Long Dated Options, which are proposed to be listed subject to ASX requirements, will expire on August 31, 2026. The options are attached to fully paid ordinary shares under a placement approved at the general meeting on December 29, 2023. The offer is available to invitees determined by the company and closes on January 5, 2024. The announcement also included the resignation of CFO Kathryn Andrews and the appointment of Phillip Hains as the new CFO effective January 31, 2024.